First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study

被引：0
|
作者：
Djelila Allouache
Sulochana R Gawande
Michele Tubiana-Hulin
Nicole Tubiana-Mathieu
Sophie Piperno-Neumann
Fawzia Mefti
Laurence Bozec
Jean-Yves Genot
机构：
[1] Lion sur mer,Centre F. Baclesse
[2] Lilly Corporate,Eli Lilly and Company
[3] Ctr René Huguenin,undefined
[4] Hopital Dupuytren,undefined
[5] Hospital Curie,undefined
[6] Lilly France,undefined
来源：
BMC Cancer | / 5卷
关键词：
Paclitaxel; Gemcitabine; Metastatic Breast Cancer; Anthracyclines; Inflammatory Breast Cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Phase II study biweekly paclitaxel, doxorubicin and gemcitabine as first line chemotherapy for metastatic breast cancer (MBC).
    Sanchez-Rovira, P
    González, E
    Porras, I
    Jaén, A
    Medina, B
    Fernández, M
    Mohedano, N
    Lozano, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S52 - S52
  • [22] Phase II Study of Bevacizumab in Combination with Docetaxel and Capecitabine for the First-Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer
    Musolino, A.
    Bisagni, G.
    De Matteis, A.
    Nuzzo, F.
    Ardizzoni, A.
    Crino, L.
    Gamucci, T.
    Passalacqua, R.
    Gnoni, R.
    Boni, C.
    CANCER RESEARCH, 2010, 70
  • [23] Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial
    Fogelman, David
    Jafari, Mehrdad
    Varadhachary, Gauri R.
    Xiong, Henry
    Bullock, Susie
    Ozer, Harold
    Lin, E.
    Morris, Jeffrey
    Cunningham, Patti
    Bennett, Bronwyn
    Abbruzzese, James L.
    Wolff, Robert A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (06) : 1431 - 1438
  • [24] Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC)
    Gluck, S.
    Lobo, C.
    Reis, I.
    Lopes, G.
    Carmody, C.
    Tukia, K.
    Hurley, J.
    Seo, P.
    Silva, O.
    Slingerland, J.
    Welsh, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] Phase I/II study of gemcitabine with pegylated liposomal doxorubicin as first-line therapy in Asian women with metastatic breast cancer
    Wong, Zee-Wan
    Ang, Peter Cher-Siang
    Chowbay, Balram
    Wong, Nan-Soon
    See, Hui-Ti
    Khoo, Kei-Siong
    BREAST, 2008, 17 (05): : 517 - 522
  • [26] Final results of first-line weekly paclitaxel plus gemcitabine in metastatic breast cancer (MBC): an AERO phase II trial
    Mousseau, M.
    Serin, D.
    Goubely-Brewer, Y.
    Petit, T.
    Priou, F.
    Zelek, L.
    BULLETIN DU CANCER, 2007, 94 (06) : 569 - 570
  • [27] Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study
    Neri, Bruno
    Vannini, Laura
    Giordano, Clara
    Grifoni, Raffaella
    Pantaleo, Pietro
    Baldazzi, Valentina
    Crisci, Alfonso
    Lapini, Alberto
    Raugei, Andrea
    Carini, Marco
    ANTI-CANCER DRUGS, 2007, 18 (10) : 1207 - 1211
  • [28] Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for anthracycline-naive metastatic breast cancer: A translational research
    Passardi, Alessandro
    Massa, Ilaria
    Gianni, Lorenzo
    Milandri, Carlo
    Zumaglini, Federica
    Tesei, Anna
    Maltoni, Roberta
    Rudnas, Britt
    Amadori, Dino
    ANNALS OF ONCOLOGY, 2005, 16 : 18 - 18
  • [29] Combination versus sequential paclitaxel plus gemcitabine as first-line chemotherapy for women with metastatic breast cancer: a prospective randomized phase II study
    Shao, Bin
    Song, Guohong
    Li, Huiping
    Di, Lijun
    Jiang, Hanfang
    Liang, Xu
    Yan, Ying
    Zhang, Ruyan
    Ran, Ran
    Wang, Jing
    Liu, Xiaoran
    You, Miaoning
    JOURNAL OF BUON, 2018, 23 (06): : 1583 - 1590
  • [30] Paclitaxel versus doxorubicin as first-line therapy for metastatic breast cancer
    Tanner, J
    Kuhnt, T
    STRAHLENTHERAPIE UND ONKOLOGIE, 2000, 176 (09) : 435 - 436
12345